文献速递肝病

替诺福韦联合或不联合聚乙二醇干扰素α并计划性停药治疗成人慢性乙型肝炎的随机试验

Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B.
PubMed 文献 · Am J Gastroenterol · 2022-12-23

这项随机试验纳入201例慢性乙型肝炎成人,比较替诺福韦联合聚乙二醇干扰素α-2a治疗24周后继续替诺福韦至192周并停药随访至240周与单用替诺福韦的疗效。主要终点第240周HBsAg清除率两组无显著差异(5.3% vs 4.1%,P=0.73),联合组HBsAg下降和清除出现更早。治疗前HBeAg阳性和HBV亚基因型A2与HBsAg清除强相关。

要点

  • 第240周HBsAg清除率联合组5.3% vs 单药组4.1%,无显著差异(P=0.73)。
  • 第24周qHBsAg下降≥1 logIU/mL者联合组28% vs 单药组6%(P=0.04)。
  • HBsAg清除在HBV亚基因型A2者中7/12(58%),其他基因型者中2/189(1%)。

核心结论

  • 聚乙二醇干扰素联合替诺福韦后按方案停用替诺福韦可使HBsAg清除出现更早,但未提高第240周HBsAg清除率。
  • 治疗前HBeAg阳性和HBV亚基因型A2与HBsAg清除强相关。

研究设计与样本

  • 随机(1:1)试验,替诺福韦酯治疗192周,联合或不联合聚乙二醇干扰素α-2a治疗前24周,第192周停用替诺福韦并随访48周至第240周。
  • 共201例受试者随机分配至联合组(n=102)或替诺福韦单药组(n=99);52%为HBeAg阳性,基因型A/A2分别占12%/6%,7%有肝硬化。

主要发现

  • 治疗结束(第192周)时6例HBsAg清除,联合组5例(5.3%),单药组1例(1.0%)(P=0.09)。
  • 第240周时9例HBsAg清除,联合组5.3%,单药组4.1%(P=0.73)。
  • 第24周qHBsAg下降≥1 logIU/mL者联合组28%,单药组6%(P=0.04)。
  • HBsAg清除在HBV亚基因型A2者中7/12(58%)(均为HBeAg阳性),其他基因型者中2/189(1%)。
  • HBsAg清除在HBeAg阳性者中8/93(8.6%),HBeAg阴性者中1/87(1.1%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Hepatitis B surface antigen (HBsAg) loss is associated with improved long-term outcomes of patients with chronic hepatitis B but is infrequently achieved with current monotherapies. We assessed whether combination strategies that included treatment withdrawal enhanced HBsAg loss. METHODS: A randomized (1:1) trial of tenofovir disoproxil fumarate (TDF) for 192 weeks with or without peginterferon (PegIFN) alfa-2a for the first 24 weeks, followed by withdrawal of TDF at week 192 with 48 weeks of off-treatment follow-up to week 240. The primary end point was HBsAg loss at week 240. RESULTS: Of 201 participants (52% HBeAg positive, 12%/6% genotype A/A2, 7% cirrhosis) randomized to TDF + PegIFN (n = 102) or TDF alone (n = 99), 6 participants had lost HBsAg at the end of the treatment phase (week 192), 5 (5.3%) in the combination group, and 1 (1.0%) in the TDF alone group ( P = 0.09). By week 240, 9 participants had cleared HBsAg, 5.3% in combination, and 4.1% in monotherapy arms ( P = 0.73). HBsAg decline and loss occurred earlier with TDF + PegIFN than TDF, with a ≥1-logIU/mL qHBsAg decline by week 24 in 28% in TDF + PegIFN compared with 6% in TDF ( P = 0.04). HBsAg loss occurred in 7 of 12 (58%) with hepatitis B virus subgenotype A2 (all HBeAg positive) compared with only 2 of 189 (1%) with other hepatitis B virus genotypes and in 8 of 93 (8.6%) HBeAg positive vs 1 of 87 (1.1%) HBeAg negative. DISCUSSION: PegIFN combined TDF followed by protocolized TDF withdrawal led to earlier but not higher percentages of HBsAg clearance. Pretreatment HBeAg positivity and subgenotype A2 were strongly associated with HBsAg clearance.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Terrault NA, Lok AS, Wahed AS, et al. Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B. Am J Gastroenterol. 2022. PMID: 36599136. doi:10.14309/ajg.0000000000002125

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。